Literature DB >> 7357079

Fibrinolytic states in a patient with congenital deficiency of alpha 2-plasmin inhibitor.

N Aoki, Y Sakata, M Matsuda, K Tateno.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7357079

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

1.  Localization of the binding site of tissue-type plasminogen activator to fibrin.

Authors:  A Ichinose; K Takio; K Fujikawa
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

2.  Organization of the human alpha 2-plasmin inhibitor gene.

Authors:  S Hirosawa; Y Nakamura; O Miura; Y Sumi; N Aoki
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

3.  Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay.

Authors:  P C Harpel
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

4.  Rapid purification of a high-affinity plasminogen activator from human blood plasma by specific adsorption on fibrin/Celite.

Authors:  S S Husain; B Lipinski; V Greuwich
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

5.  The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.

Authors:  D Rouy; E Anglés-Cano
Journal:  Biochem J       Date:  1990-10-01       Impact factor: 3.857

6.  Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.

Authors:  Y Sakata; N Aoki
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

7.  Molecular basis for congenital deficiency of alpha 2-plasmin inhibitor. A frameshift mutation leading to elongation of the deduced amino acid sequence.

Authors:  O Miura; S Hirosawa; A Kato; N Aoki
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.